新冠疫情期间诊断的癌症患者短期生存分析
该研究基于SEER-21数据库分析2015至2021年侵袭性癌症患者,比较2020和2021年诊断者与疫情前趋势的1年病因特异性生存率。
要点
- 2020和2021年诊断的早期和晚期癌症患者1年CSS均较疫情前趋势显著下降。
- 晚期诊断的1年CSS绝对下降幅度大于早期诊断。
核心结论
- 2020和2021年诊断的癌症患者短期生存较2015至2019年诊断者更差。
- 提示新冠疫情头两年癌症诊疗中断带来实质性危害。
研究设计与样本
- 基于SEER-21数据库的人群队列研究,纳入2015年1月1日至2021年12月31日诊断的侵袭性癌症患者。
- 共1 008 012例在疫情头两年诊断,其中2020年473 781例、2021年534 231例。
主要发现
- 早期诊断1年CSS绝对下降:2020年-0.44(95%CI -0.54至-0.34)个百分点,2021年-0.27(95%CI -0.37至-0.16)个百分点。
- 晚期诊断1年CSS绝对下降:2020年-1.34(95%CI -1.75至-0.93)个百分点,2021年-1.20(95%CI -1.69至-0.71)个百分点。
- 其他非西班牙裔种族及65岁及以上人群晚期诊断的1年CSS绝对下降均大于1.00个百分点。
- 2020和2021年早期食管癌1年CSS分别下降3.89和3.67个百分点、早期结直肠癌分别下降1.08和0.78个百分点、晚期前列腺癌分别下降0.64和0.77个百分点。
临床怎么用
- 肿瘤内科医生应关注疫情期间诊断患者的短期生存风险,尤其晚期及高龄、少数种族人群。
- 对疫情期间诊断的早期食管癌、结直肠癌及晚期前列腺癌患者加强随访与支持。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The effects of COVID-19 pandemic-related disruptions on cancer diagnosis in the US have been widely observed, but their impact on short-term survival has not been assessed. OBJECTIVE: To examine 1-year cause-specific survival (CSS) rates among patients diagnosed with cancer during 2020 and 2021 using high-quality cancer registry data. DESIGN, SETTING, AND PARTICIPANTS: This population-based cohort study of cancer survival between 2015 and 2021 used the Surveillance, Epidemiology, and End Results 21 Registries (SEER-21) database. The population included individuals with an invasive cancer diagnosis and complete follow-up reported to registries included in SEER-21 between January 1, 2015, and December 31, 2021. Data were analyzed from May 13 to May 27, 2025. EXPOSURE: COVID-19 pandemic. MAIN OUTCOMES AND MEASURES: The primary outcome was 1-year CSS rates by stage at diagnosis for patients diagnosed with cancer in 2020 and 2021 compared with trends in 1-year CSS rates among patients diagnosed between 2015 and 2019. Additional site-specific analyses were performed on common cancer sites identified as having low survival (5-year relative survival <33%) or high incidence and high survival (incidence >20.0 per 100 000 and 5-year relative survival ≥66%). RESULTS: A total of 1 008 012 individuals were diagnosed with cancer during the first 2 years of the COVID-19 pandemic, including 473 781 in 2020 (50.1% female; 51.0% diagnosed at ≥65 years; 11.5% Black, 15.8% Hispanic, 64.1% White, and 7.4% other race) and 534 231 in 2021 (50.3% female; 51.9% diagnosed at ≥65 years; 51.9% diagnosed at ≥65 years; 11.7% Black, 16.2% Hispanic, 62.9% White, and 7.9% other race). Compared with prepandemic trends, significant absolute reductions in 1-year CSS rates occurred for early-stage diagnoses in 2020 (-0.44 [95% CI, -0.54 to -0.34] percentage points) and 2021 (-0.27 [95% CI, -0.37 to -0.16] percentage points) and late-stage diagnoses in 2020 (-1.34 [95% CI, -1.75 to -0.93] percentage points) and 2021 (-1.20 [95% CI, -1.69 to -0.71] percentage points). Survival reductions resulted in an estimated 17 390 more cancer-related deaths (13.1%) within 1 year of diagnosis than expected during the first 2 years of the COVID-19 pandemic. Absolute survival reductions greater than 1.00 percentage point occurred in both years for late-stage diagnoses among individuals of other non-Hispanic race and ethnicity (ie, American Indian and Alaska Native, Asian or Pacific Islander, or unknown race) and individuals aged 65 years or older. Significant site-specific survival reductions also existed in both 2020 and 2021, respectively, for early-stage diagnoses of esophageal cancer (-3.89 and -3.67 percentage points) and colorectal cancer (-1.08 and -0.78 percentage points) and late-stage diagnoses of prostate cancer (-0.64 and -0.77 percentage points). CONCLUSIONS AND RELEVANCE: This cohort study found that individuals diagnosed with cancer in 2020 and 2021 experienced worse short-term survival than those diagnosed between 2015 and 2019, suggesting substantial harms associated with cancer care disruptions during the first 2 years of the COVID-19 pandemic.
引用
- Burus T, Damgacioglu H, Huang B, et al. Survival of Patients Diagnosed With Cancer During the COVID-19 Pandemic. JAMA Oncol. 2026. PMID: 41642595. doi:10.1001/jamaoncol.2025.6332
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。